BRPI0516810A - uso de conjugados de lipìdios no tratamento de doenças - Google Patents
uso de conjugados de lipìdios no tratamento de doençasInfo
- Publication number
- BRPI0516810A BRPI0516810A BRPI0516810-4A BRPI0516810A BRPI0516810A BR PI0516810 A BRPI0516810 A BR PI0516810A BR PI0516810 A BRPI0516810 A BR PI0516810A BR PI0516810 A BRPI0516810 A BR PI0516810A
- Authority
- BR
- Brazil
- Prior art keywords
- lipid
- diseases
- treatment
- lipid conjugates
- dimer
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 2
- 201000010105 allergic rhinitis Diseases 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000539 dimer Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/989,607 US7772196B2 (en) | 2000-01-10 | 2004-11-17 | Use of lipid conjugates in the treatment of diseases |
| US10/989,606 US7811999B2 (en) | 2000-01-10 | 2004-11-17 | Use of lipid conjugates in the treatment of diseases |
| PCT/US2005/006591 WO2005084307A2 (en) | 2004-03-02 | 2005-03-02 | Use of lipid conjugates in the treatment of disease |
| PCT/IL2005/001225 WO2006054304A2 (en) | 2004-11-17 | 2005-11-17 | Use of lipid conjugates in the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516810A true BRPI0516810A (pt) | 2008-09-23 |
Family
ID=39619055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516810-4A BRPI0516810A (pt) | 2004-11-17 | 2005-11-17 | uso de conjugados de lipìdios no tratamento de doenças |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1819345A4 (de) |
| JP (2) | JP2008520650A (de) |
| CN (1) | CN101175499B (de) |
| AU (1) | AU2005305456B2 (de) |
| BR (1) | BRPI0516810A (de) |
| CA (1) | CA2587883A1 (de) |
| EA (1) | EA012138B1 (de) |
| IL (3) | IL183227A0 (de) |
| MX (1) | MX2007005975A (de) |
| WO (1) | WO2006054304A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090325876A1 (en) * | 2004-09-29 | 2009-12-31 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases associated with vasculature |
| WO2008100912A1 (en) * | 2007-02-12 | 2008-08-21 | The General Hospital Corporation | Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
| JP2012526819A (ja) * | 2009-05-11 | 2012-11-01 | イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド | 脂質−ポリマー複合体、その調製、及びその使用 |
| CA3153463A1 (en) | 2012-10-29 | 2014-05-08 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
| EP3020417A4 (de) * | 2013-07-10 | 2017-01-18 | Seikagaku Corporation | Pharmazeutische zusammensetzung zur respiratorischen verabreichung |
| EP4292651A3 (de) * | 2016-06-27 | 2024-03-13 | Ohio State Innovation Foundation | Liponukleotidbasierte therapie für ards |
| CN110198728A (zh) | 2016-11-17 | 2019-09-03 | 莱诺翁股份有限公司 | 用谷胱甘肽组合物治疗呼吸道疾病和感染 |
| DK3710036T3 (da) | 2017-11-17 | 2025-01-13 | Renovion Inc | Stable ascorbic acid compositions and methods of using the same |
| JP2025502856A (ja) | 2022-01-04 | 2025-01-28 | レノビオン インコーポレイテッド | グルタチオン塩を含む水溶液 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84252A (en) * | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
| JPH0232013A (ja) * | 1988-07-20 | 1990-02-01 | Denki Kagaku Kogyo Kk | 点鼻剤 |
| US6022866A (en) * | 1991-07-03 | 2000-02-08 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| ES2044781B1 (es) * | 1992-04-14 | 1994-10-01 | Menarini Lab | Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2 |
| JP3714683B2 (ja) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
| KR100381449B1 (ko) * | 1994-10-14 | 2003-07-18 | 더 리포좀 컴퍼니, 인코퍼레이티드 | 에테르지질리포좀과이들의제약학적용도 |
| US6180596B1 (en) * | 1995-05-18 | 2001-01-30 | Wisconsin Alumni Research Foundation | Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities |
| US6071532A (en) * | 1996-10-15 | 2000-06-06 | Emory University | Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof |
| JPH11147901A (ja) * | 1997-11-19 | 1999-06-02 | Maruho Co Ltd | カリクレイン−キニン系阻害剤 |
| US6162787A (en) * | 1999-04-02 | 2000-12-19 | Immudyne, Inc. | Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions |
| US7101859B2 (en) * | 2000-01-10 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
| CA2397016C (en) * | 2000-01-10 | 2011-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
| US7141552B2 (en) * | 2000-01-10 | 2006-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
-
2005
- 2005-11-17 WO PCT/IL2005/001225 patent/WO2006054304A2/en not_active Ceased
- 2005-11-17 BR BRPI0516810-4A patent/BRPI0516810A/pt not_active Application Discontinuation
- 2005-11-17 CA CA002587883A patent/CA2587883A1/en not_active Abandoned
- 2005-11-17 EA EA200701077A patent/EA012138B1/ru not_active IP Right Cessation
- 2005-11-17 JP JP2007542507A patent/JP2008520650A/ja active Pending
- 2005-11-17 CN CN2005800467713A patent/CN101175499B/zh not_active Expired - Fee Related
- 2005-11-17 MX MX2007005975A patent/MX2007005975A/es active IP Right Grant
- 2005-11-17 AU AU2005305456A patent/AU2005305456B2/en not_active Ceased
- 2005-11-17 EP EP05808267A patent/EP1819345A4/de not_active Withdrawn
-
2007
- 2007-05-15 IL IL183227A patent/IL183227A0/en unknown
-
2011
- 2011-04-07 IL IL212214A patent/IL212214A0/en unknown
- 2011-04-07 IL IL212215A patent/IL212215A0/en unknown
- 2011-09-13 JP JP2011199088A patent/JP2012001559A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012001559A (ja) | 2012-01-05 |
| EA200701077A1 (ru) | 2008-04-28 |
| IL183227A0 (en) | 2007-08-19 |
| EP1819345A2 (de) | 2007-08-22 |
| WO2006054304A2 (en) | 2006-05-26 |
| CA2587883A1 (en) | 2006-05-26 |
| IL212214A0 (en) | 2011-06-30 |
| JP2008520650A (ja) | 2008-06-19 |
| MX2007005975A (es) | 2007-10-08 |
| IL212215A0 (en) | 2011-06-30 |
| AU2005305456B2 (en) | 2011-05-19 |
| WO2006054304A3 (en) | 2007-01-25 |
| EP1819345A4 (de) | 2012-04-18 |
| CN101175499B (zh) | 2010-12-22 |
| EA012138B1 (ru) | 2009-08-28 |
| AU2005305456A1 (en) | 2006-05-26 |
| CN101175499A (zh) | 2008-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005051297A3 (en) | Combination drug therapy to treat obesity | |
| BRPI0717697A2 (pt) | composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos | |
| BR0316264A (pt) | Medicamento para tratamento de doença pulmonar obstrutiva crÈnica | |
| WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
| BRPI0610321B8 (pt) | imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica | |
| MX2009001534A (es) | Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva. | |
| BR0012888A (pt) | Inibidores derivados de purina de proteìna tirosina sic quinase | |
| BRPI0608297A2 (pt) | composições de lipossomos | |
| CL2007002043A1 (es) | Compuestos derivados de pirimidinas sustituidos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, hipertension pulmonar, fibrosis pulmonar, fibro | |
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| BRPI0407508A (pt) | derivados de bifenila | |
| BRPI0410721A (pt) | composições farmacêuticas espumáveis e métodos para tratamento de um distúrbio | |
| MXPA05011208A (es) | Uso de ivermectina para el tratamiento de desordenes dermatologicos. | |
| BRPI0918194A2 (pt) | ''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação | |
| WO2007009539A3 (en) | Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases | |
| MX2009008363A (es) | Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2. | |
| CY1118179T1 (el) | Φαρμακευτικη συνθεση | |
| BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
| BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
| WO2006108582A3 (en) | Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| BRPI0516810A (pt) | uso de conjugados de lipìdios no tratamento de doenças | |
| NO20070146L (no) | 4-fenylpyrimidin-2-karbonitril-derivater | |
| EP2305639A3 (de) | Organische verbindungen | |
| BRPI0514735B8 (pt) | derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |